

# High Mobility Group Protein B1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/HB72DAEF418DEN.html>

Date: September 2020

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: HB72DAEF418DEN

## Abstracts

High Mobility Group Protein B1 - Pipeline Review, H2 2020

### SUMMARY

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene. HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus. High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Cardiovascular, Central Nervous System, Gastrointestinal, Oncology, Dermatology, Musculoskeletal Disorders, Other Diseases and Respiratory which include indications Parkinson's Disease, Sepsis, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Brain (Head) Trauma, Cardiomyopathy, Cerebral Infarction (Brain Infarction), Chronic Liver Disease, Coronavirus Disease 2019 (COVID-19), Dilated Cardiomyopathy, Epidermolysis Bullosa, Epilepsy, Influenzavirus A

Infections, Ischemic Cardiomyopathy, Liver Diseases, Myelodysplastic Syndrome, Osteoarthritis, Refractory Acute Myeloid Leukemia and Stroke.

The latest report High Mobility Group Protein B1 - Pipeline Review, H2 2020, outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)

The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects

The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding High Mobility

Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Overview

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Companies Involved in Therapeutics Development

Afecta Pharmaceuticals Inc

Affibody AB

Chimerix Inc

Shionogi & Co Ltd

TheraSource LLC

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Drug Profiles

ABY-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AFX-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dociparstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Drugs to Inhibit HMGB1 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### JH-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Recombinant High Mobility Group Protein B1 Replacement for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## redasemtide trifluoroacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## TSA-521 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Dormant Products

## High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Product Development Milestones

## Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Actavalon Inc, H2 2020

Pipeline by Active Biotech AB, H2 2020

Pipeline by Ampio Pharmaceuticals Inc, H2 2020

Pipeline by AnToIRx Inc, H2 2020

Pipeline by Bayer AG, H2 2020

Pipeline by Dermavant Sciences Inc, H2 2020

Pipeline by Hercules Pharmaceuticals BV, H2 2020

Pipeline by Hutchison MediPharma Ltd, H2 2020

Pipeline by Ikena Oncology Inc, H2 2020

Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020

Pipeline by Magenta Therapeutics Inc, H2 2020

Pipeline by Pfizer Inc, H2 2020

Pipeline by Phenex Pharmaceuticals AG, H2 2020

Pipeline by Shenogen Pharma Group Ltd, H2 2020

Pipeline by Sol-Gel Technologies Ltd, H2 2020

Pipeline by Welichem Biotech Inc, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

Afecta Pharmaceuticals Inc

Affibody AB

Chimerix Inc

Shionogi & Co Ltd

TheraSource LLC

## I would like to order

Product name: High Mobility Group Protein B1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/HB72DAEF418DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HB72DAEF418DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970